Hohhot's rising vaccine industry

Hohhot has seen rapid momentum in the construction of key projects within its biopharmaceutical sector, driving the city toward becoming a leading hub for bio-innovation.

The Hohhot bureau of science and technology announced a breakthrough by Inner Mongolia Huaxi Biology Technology Co on Aug 24, as the company's independently developed Brucella gene-deletion live vaccine (strain RM6, rough type) has passed veterinary biological production and inspection reports, entering large-scale production. Experts estimated that the vaccine is expected to generate an annual revenue of 140 million yuan ($19.57 million) once in full production.

Since the 13th Congress of the CPC Representatives in Hohhot in 2021, the city's biopharmaceutical industry has been identified as one of six strategic industrial clusters.

A series of high-level projects have since taken root, including the Opcel animal serum and culture medium R&D project, the Phase II project of Wanrui Biotech's industrialization base, and Ringpu Biotech's high-end veterinary drug industrialization project in the Inner Mongolia autonomous region.

Hohhot aims to attract or incubate over 100 synthetic biology enterprises by 2027, with the sector's output value projected to reach 50 billion yuan. By 2030, the city aspires to become a national benchmark for synthetic biology and a first-class hub for veterinary vaccine R&D and production in China.